← Back to Home

Graviton BioScience

Private

#Rare Disease #Friedreich's Ataxia #Neurology

Therapeutics company focused on Friedreich's Ataxia. Received IND clearance for GV101 from the FDA in August 2026.

Company Info

Sector:Rare Disease / Neurology

Headquarters:New Jersey, USA

Founded:2022

Website:gravitoncorp.com/

Upcoming Milestones & Key Dates

2026 H2

Clinical Trial

Phase 1 dosing begins for GV101

Clinical Development Pipeline

GV101

Target: Undisclosed

Friedreich's Ataxia

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Recent News

Clinical Regulatory•Aug 11, 2026•PR Newswire FDA

Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia ↗

Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia

Leadership Team

Careers & Job Openings

See all open roles